Related by context. All words. (Click for frequent words.) 79 Secondary efficacy endpoints 78 Primary endpoints 76 Secondary endpoints included 76 Secondary endpoints include 73 secondary endpoints 70 Efficacy endpoints 69 secondary endpoint 69 secondary efficacy endpoint 69 endoscopic remission 69 secondary efficacy endpoints 68 CIMZIA TM certolizumab pegol 67 exploratory endpoints 67 pharmacodynamic endpoints 66 clinically meaningful improvements 66 pharmacokinetics PK 66 RECIST Response Evaluation Criteria 66 Montgomery Asberg Depression 66 Events MACE 66 postintervention 66 mcg QD 66 patients evaluable 66 composite endpoint 65 BENICAR HCT 65 chlorambucil 65 Key secondary endpoints 65 WOMAC pain 65 galiximab 65 DAS# CRP 65 ADAS Cog 65 Psoriasis Area 65 progression TTP 65 partial remissions 65 morphometric vertebral fractures 65 IBDQ 65 oxycodone CR 65 Rating Scale MADRS 65 prospectively defined 65 Montgomery Åsberg Depression 65 primary efficacy endpoint 65 Index CDAI 65 Exclusion criteria 65 primary efficacy endpoints 64 ADCS CGIC 64 clinically meaningful improvement 64 pegylated interferon alfa 2b 64 Crohn Disease Activity 64 ATACAND 64 CRp 64 YMRS 64 abacavir lamivudine 64 FOLPI 64 HBeAg positive patients 64 CIMZIA ™ 64 pharmacokinetic parameters 64 genotypic resistance 64 Subgroup analysis 64 SGRQ 64 pharmacodynamic PD 64 efficacy endpoints 64 ACTEMRA TM 64 metabolic parameters 64 achieved statistical significance 64 relapsed MM 64 postmenopausal osteoporotic women 64 IPSS 64 ADAS cog 64 calculated creatinine clearance 64 posttreatment 64 hematological parameters 64 novel VDA molecule 64 CDAI 64 CIMZIA TM 64 evaluable 64 serum phosphorous 64 desvenlafaxine succinate 64 Scale EDSS 63 prospectively stratified 63 Flu Cy 63 primary endpoints 63 tipranavir r 63 oblimersen 63 CCyR 63 primary endpoint 63 bosentan 63 #mg/day [002] 63 crizotinib PF # 63 GAMMAGARD 63 HAM D# 63 HBeAg negative patients 63 phonophobia 63 irbesartan 63 HDRS 63 evaluable patients 63 melphalan prednisone 63 VELCADE melphalan 63 Brief Psychiatric 63 NMIBC 63 â ‰ ¥ 63 pharmacodynamic effects 63 Alzheimer Disease Assessment 63 comparator arm 63 4mg/kg 63 nausea photophobia 63 cytogenetic response 63 catheter occlusion 63 TLUS 63 demonstrated clinically meaningful 63 annualized relapse 63 Neuropsychiatric Inventory NPI 63 pharmacodynamic 63 Median progression 63 nasal symptom 63 #mg BID [003] 62 recurrent glioblastoma multiforme 62 Subgroup analyzes 62 FOLFOX4 62 glycosylated hemoglobin levels 62 univariate 62 International Prostate Symptom 62 COPD exacerbations 62 certolizumab 62 Response Evaluation Criteria 62 haematologic 62 undetectable HBV DNA 62 NIHSS 62 HAQ DI 62 SVR# 62 BENICAR 62 posaconazole 62 baseline HbA1c 62 Pharmacokinetics PK 62 ug kg 62 mg BID 62 postoperative AF 62 APTIVUS r 62 Scale PANSS 62 pharmacodynamic parameters 62 6R BH4 62 tolerability profiles 62 headache nasopharyngitis 62 dosage regimens 62 prespecified secondary 62 HRQL 62 p = #.# [004] 62 timepoints 62 hemoglobin A1c HbA1c 62 elotuzumab 62 angiographic outcomes 62 specific antigen PSA 62 Kaplan Meier analysis 62 clinical endpoints 62 concomitant medications 62 MADRS score 62 evaluating REVLIMID 62 virologic responses 62 insulin detemir 62 RAPAFLO R 62 oral FTY# 62 MADRS 62 Lupuzor ™ 62 placebo p = 62 UPDRS motor 62 β blockers 62 quetiapine XR 62 interferon gamma 1b 62 cisplatin gemcitabine 62 binary restenosis 62 Doxil ® 62 clinicopathological features 62 #mg/day [001] 62 lipid lowering agents 62 standard chemotherapy regimen 62 hemostatic efficacy 62 P = .# 62 teriflunomide 62 active comparator 61 subscale scores 61 ritonavir boosted 61 CANCIDAS 61 methotrexate monotherapy 61 covariate 61 XIENCE V PROMUS Stent 61 tolvaptan 61 prespecified 61 biochemical recurrence 61 tumor progression TTP 61 Major Adverse Cardiac 61 GOUT 61 postdose 61 INCB# [003] 61 QoL 61 lipid parameters 61 urinary N telopeptide 61 neurocognitive function 61 rosuvastatin #mg 61 Androxal TM 61 PANSS total 61 NIH CPSI 61 mucosal healing 61 zonisamide SR 61 CR nPR 61 pharmacokinetic PK profile 61 PCWP 61 Solid Tumors criteria 61 surrogate endpoint 61 Negative Syndrome 61 Unified Parkinson Disease 61 Baseline characteristics 61 sUA 61 lopinavir r arm 61 PASI scores 61 pharmacodynamics PD 61 Pharmacokinetic parameters 61 splenectomized patients 61 intact parathyroid hormone 61 viral kinetics 61 HRQOL 61 EURIDIS 61 Kaplan Meier estimates 61 TEAEs 61 IFN α 61 HAMD 61 PANSS 61 riociguat 61 trials RCTs 61 liver histology 61 coadministration 61 aspartate aminotransferase AST 61 AST ALT 61 tirofiban 61 PREZISTA r 61 pharmacokinetic PK 61 laboratory abnormalities 61 glycosylated hemoglobin HbA1c 61 docetaxel prednisone 61 #mg QD [002] 61 HRQoL 61 MACCE 61 histologic 61 HER2 positive metastatic breast 61 eplerenone 61 SSRI SNRI 61 tanespimycin 61 Free Survival PFS 61 Pharmacodynamic 61 Folfox 61 antiarrhythmic drug 61 serum HBV DNA 61 postoperative chemotherapy 61 FluCAM arm 61 activated partial thromboplastin 61 randomized Phase 2b 61 achieved ACR# 61 Pharmacokinetic 61 LEXIVA r 61 placebo dexamethasone 61 methacholine challenge 61 Kaplan Meier 61 tolerability pharmacokinetics 61 KRAS status 61 ADCS ADL 61 olmesartan 61 posttransplant 61 DAS# [002] 61 MYCAMINE 61 timepoint 61 inflammatory biomarkers 61 pharmacokinetic characteristics 61 glatiramer acetate 61 coinfected patients 61 candesartan cilexetil 61 STRIDE PD 61 HCV RESPOND 2 61 remission CR 61 TAXUS VI 61 symptomatic VTE 61 subscales 61 preintervention 61 tiotropium 61 metastatic GIST 61 clinically meaningful reductions 61 CTEPH 61 dosing cohort 60 plus prednisone 60 mg RDEA# 60 demonstrated antitumor activity 60 carotid IMT 60 nondiabetic patients 60 abdominal pain abdominal discomfort 60 HbA 1c levels 60 univariate analysis 60 dose cohort 60 mesalamine granules 60 intima media thickness 60 telaprevir dosed 60 ACR# ACR# 60 F FDG PET 60 HER2 expression 60 prednisone prednisolone plus 60 ribavirin RBV 60 pCR 60 DAPT 60 adalimumab Humira 60 IIIa inhibitor 60 demonstrated statistically significant 60 nicardipine 60 pain palliation 60 alteplase 60 pegylated liposomal doxorubicin 60 plasma uric acid 60 8mg/kg 60 virological response 60 Pain Intensity 60 elevated ALT 60 plus dexamethasone 60 adjuvant GIST 60 biochemical relapse 60 sinus rhythm 60 mg/m2 dose 60 low dose cytarabine 60 symptom severity 60 BEXXAR Therapeutic Regimen 60 mg QD 60 HES CEL 60 WOMAC TM 60 hepatic enzyme 60 echocardiographic parameters 60 NATRECOR R 60 RECIST criteria 60 Traficet EN 60 lopinavir r 60 Meta analyzes 60 nonrandomized 60 FOLFOX6 60 OADs 60 GERD symptom 60 MoxDuo TM IR 60 serum phosphorus 60 serum urate 60 mg kg dose 60 salmeterol fluticasone 60 #.#mg/dL 60 ß blockers 60 aspirin clopidogrel 60 free survival PFS 60 retinal thickness 60 CR CRu 60 K ras mutations 60 tumor necrosis 60 pharmacokinetics pharmacodynamics 60 NATRECOR ® 60 hsCRP levels 60 QTc prolongation 60 bortezomib refractory 60 AGILECT ® 60 primary hypercholesterolemia 60 nab paclitaxel 60 Visual Analogue Scale VAS 60 DAS# remission 60 ascending dose 60 meta regression 60 NYHA functional class 60 antiangiogenic therapy 60 GLIADEL R Wafer 60 PSA nadir 60 EDARBI 60 -#.# log# copies mL 60 oral rivaroxaban 60 tolerability 60 HIV HCV coinfected 60 pharmacokinetic profiles 60 KRAS mutations occur 60 symptom exacerbation 60 TAXUS Express Stent 60 PEGINTRON TM 60 neurologic progression 60 TYSABRI treated 60 severe exacerbations 60 mcg kg 60 response CCyR 60 virologic response 60 prognostic indicators 60 tipranavir ritonavir 60 Ranolazine 60 dose escalation phase 60 angiotensin converting enzyme inhibitor 60 COPD exacerbation 60 neutropenia thrombocytopenia 60 plus methotrexate 60 R# #mg BID 60 Severity Index PASI 60 nasopharyngitis headache 60 % CI #.#-#.# [003] 60 tapentadol ER 60 clopidogrel Plavix 60 Fludara 60 specified secondary endpoints 60 viral kinetic 60 erlotinib Tarceva ® 60 chemoradiation therapy 60 Hematologic 60 fosamprenavir 60 mg qd 60 CTAP# Capsules 60 radiotherapy RT 60 peginterferon alfa 2a #KD 60 atazanavir ritonavir 60 hypoglycemic events 60 serum cortisol 60 serum HCV RNA 59 TDF FTC 59 hemodynamic measurements 59 estimated glomerular filtration 59 nadolol 59 beta blocker therapy 59 hypogonadal men 59 Thrombolysis 59 QIDS SR 59 extrapyramidal symptoms 59 lumbar spine BMD 59 Amrubicin 59 hyperphenylalaninemia HPA due 59 plasma lipids 59 fosbretabulin 59 unresectable HCC 59 Score IPSS 59 oxymorphone ER 59 coronary stenosis 59 nonfatal MI 59 moderate renal impairment 59 CHARM Added 59 phase IIIb 59 peginterferon alfa 59 periprocedural 59 mycophenolate mofetil 59 ZOLINZA 59 tolterodine ER 59 dyspnea 59 VcMP 59 hematologic parameters 59 posttest 59 eszopiclone 59 statistically significant improvement 59 reactogenicity 59 ARCOXIA 59 EQ 5D 59 cinacalcet 59 Tasigna prolongs 59 Endpoints 59 unfractionated heparin UFH 59 efficacy tolerability 59 estramustine 59 covariates 59 colesevelam HCl 59 non selective NSAIDs 59 BPH symptom 59 bezafibrate 59 Severity MSCS score 59 primidone 59 CLL SLL 59 EDEMA3 trial 59 systemic corticosteroid 59 spontaneous bowel movements 59 Pioglitazone 59 complete cytogenetic 59 Initiated Phase 59 dyslipidaemia 59 QD dosing 59 ULORIC 59 -#.# log# 59 myopathy rhabdomyolysis 59 adenotonsillectomy 59 trastuzumab Herceptin ® 59 lenalidomide dexamethasone 59 brachial artery flow 59 preoperative PSA 59 adenoma recurrence 59 symptomatic hyponatremia 59 gemcitabine Gemzar ® 59 alfuzosin 59 neoadjuvant 59 liver transaminases 59 endothelin receptor antagonists 59 p = #.# [002] 59 FOLFIRI 59 pharmacodynamic markers 59 saline placebo 59 evaluable subjects 59 #mg BID [001] 59 postprocedure 59 squamous histology 59 aminotransferase levels 59 concurrent chemoradiation 59 CONCERTA ® 59 HbA1C levels 59 RLAI 59 chills fever headache 59 Thal Dex 59 creatinine clearance 59 renal function 59 locoregional recurrence 59 Randomized controlled 59 docetaxel Taxotere 59 Perforomist Inhalation Solution 59 Disease Activity 59 Expanded Disability Status 59 6MWD 59 LV ejection fraction 59 serologically active patients 59 gout flares 59 ribavirin therapy 59 HBeAg seroconversion 59 candesartan 59 etanercept 59 prognostic variables 59 lymphopenia 59 evaluating Actimmune 59 Serious adverse reactions 59 FOLFOX 59 esomeprazole 59 μg kg 59 adriamycin 59 chronic thromboembolic pulmonary 59 hepatic enzymes 59 trospium 59 Natalizumab 59 Erythropoietic therapies may 59 elevated transaminases 59 imatinib therapy 59 subgroup analyzes 59 Postoperative 59 INC# 59 Score TOS 59 mRCC 59 alicaforsen enema 59 Scale EDSS score 59 fluticasone salmeterol 59 intermittent dosing 59 calcineurin inhibitor 59 MEND CABG 59 fasting plasma glucose 59 ORENCIA ® 59 flutamide 59 QTcF 59 Symptom severity 59 hematological adverse 59 Elitek 59 Visual Analog Scale 59 definite stent thrombosis 59 torsemide ER 59 oral antidiabetic medication 59 #mg BID [002] 59 nodular partial response 59 confirmed CCyR 59 systolic function 59 natriuresis 59 Scale cognitive subscale 59 dose proportionality 59 peginterferon alfa 2b 59 stage IIIb IV 59 plus OBT 59 mg TID 59 pulmonary exacerbations 59 hip BMD 59 paclitaxel carboplatin 59 pramlintide metreleptin combination 59 erection hardness 59 tolterodine 59 debulking surgery 59 liposomal doxorubicin 59 Postoperative complications 59 metastatic HRPC 59 multicenter randomized controlled 59 dose atorvastatin 59 rFVIIa 59 corrected QT interval 59 sipuleucel T 59 myocardial viability 59 everolimus eluting stents 59 peg IFN 59 PEG IFN 59 SABCS 59 fluoxetine paroxetine 59 clevidipine 59 confidence interval CI 59 mitoxantrone plus 59 cytogenic 59 DLTs 59 HbA1c levels 59 affective psychosis 59 certolizumab pegol 59 aspartate aminotransferase 59 gastrointestinal toxicities 59 histologic subtype 59 dyspnoea 59 preoperatively 59 FDA defined valvulopathy 59 NPH insulin 59 tumor histology 59 vasomotor symptoms 59 glycated hemoglobin levels 59 OAB symptoms 58 ascending doses 58 mcg albinterferon alfa 2b 58 MAGE A3 ASCI 58 noninferiority 58 PEGylated anti 58 carotid intima media 58 dose titration 58 Rasilez Tekturna 58 fasting plasma glucose FPG 58 QTc 58 Telintra 58 immunosuppressive regimen 58 acute coronary syndromes ACS 58 epoetin alpha 58 PegIFN RBV 58 pegylated interferon alfa 58 aPTT 58 baseline FEV 58 CSBM 58 prednisone prednisolone 58 HbA 1c 58 CrCl 58 weekly subcutaneous injections 58 AGILECT R 58 prognostic factors 58 biphasic insulin aspart 58 leukocyte count 58 Tiotropium 58 icatibant 58 efficacy endpoint 58 UPDRS 58 visilizumab 58 FUSILEV enhances 58 ritonavir boosted atazanavir 58 oral diclofenac 58 Pegasys ® 58 β blocker 58 cEVR 58 MMSE score 58 RoACTEMRA 58 paricalcitol 58 postoperative mortality 58 azacitidine 58 CNS LS 58 prospective multicentre 58 dacetuzumab 58 Platelet counts 58 GnRH agonist 58 ACR Pedi 58 p = NS 58 LVEF 58 Oral Fingolimod 58 #mg dose [001] 58 tamoxifen Nolvadex ® 58 Score DAS# 58 colorectal adenoma 58 NNT = 58 gemcitabine carboplatin 58 events TEAEs 58 5-fluorouracil/leucovorin 58 1mg dose 58 deep venous thromboses 58 doxorubicin cyclophosphamide 58 gemcitabine Gemzar 58 APTIVUS 58 CLARITY study 58 urate lowering 58 neutropaenia 58 lymphocytosis 58 REYATAZ r arm 58 FOLFOX regimen 58 #mg/m# [001] 58 limiting toxicity DLT 58 comorbid conditions 58 relapsed MCL 58 daily Infergen 58 adjunctive placebo 58 placebo p 58 TNFalpha 58 PREZISTA r arm 58 thromboembolic events 58 pyridostigmine 58 SPIRIVA HandiHaler 58 mCRC patients 58 PROactive study 58 CYP#D# inhibitor 58 carboplatin paclitaxel 58 serum testosterone 58 ischemic cardiomyopathy 58 macroalbuminuria 58 aldosterone antagonist 58 #.#/#.# mmHg [001] 58 trough FEV1 58 cytoreductive nephrectomy 58 nonfatal myocardial infarction 58 custirsen 58 EBMT criteria 58 NIS LL 58 undetectable HCV RNA 58 dosing cohorts 58 serum phosphate levels 58 HBeAg 58 5-FU/LV 58 PEGPH# 58 radical prostatectomy RP 58 Panzem R NCD 58 CsA 58 % Confidence Interval 58 benazepril 58 serum leptin 58 mcg BID 58 mg kg BID 58 TNF antagonist 58 carotid endarterectomy CEA 58 pretransplant 58 Score DAS 58 p = .# [002] 58 dacarbazine 58 serum triglyceride levels 58 MDS MPD 58 papillary renal cell carcinoma 58 nonresponders 58 ELACYT 58 clinically meaningful differences 58 Vidaza ® 58 -#.# ± [002] 58 anaphylactic reactions bronchospasm 58 TNF Tumor Necrosis Factor 58 perioperative complications 58 lispro 58 BoNTA 58 fasting insulin 58 preoperative chemotherapy 58 DLQI 58 TELCYTA 58 AZILECT 58 IRLS 58 angiotensin converting enzyme inhibitors 58 Randomized Evaluation 58 oral levofloxacin 58 bivariate analysis 58 Health Assessment Questionnaire 58 BMI z 58 erythrocyte sedimentation rate 58 PRE SURGE 58 docetaxel chemotherapy 58 somatostatin analog 58 hemodynamically significant 58 neutropenia dehydration dyspnea 58 attain statistical significance 58 ≥ 58 urocortin 2 58 ropivacaine 58 CHOP chemotherapy 58 limiting toxicity 58 Ceplene/IL-2 58 PRECiSE 58 pharmacodynamics 58 virologic failure 58 placebo controlled clinical 58 Mean Symptom Complex 58 prostate cancer CaP 58 response pCR 58 Solid Tumors RECIST 58 corticosteroid therapy 58 events MACE 58 Fibrillex TM 58 serum uric acid 58 receiving VICTRELIS 58 VP# [004] 58 diuretic chlorthalidone 58 REMINYL ® 58 randomized multicenter trial 58 ARCALYST ® 58 mL/min/#.# m 2 58 p = #.# [003] 58 PSADT 58 intravascular hemolysis 58 alfa 2a 58 systolic BP 58 pulmonary capillary wedge 58 HBeAg negative 58 mL kg 58 antihypertensive therapy 58 Phase IIIb clinical 58 Zemplar Capsules 58 febrile neutropenia 58 otamixaban 58 LDL triglycerides 58 prucalopride 58 CORE OM 58 decitabine 58 follicular lymphoma FL 58 multivariate analyzes 58 microbiological eradication 58 perioperatively 58 androgen deprivation 58 plus COPEGUS 58 lexidronam injection 58 LV dysfunction 58 sustained virologic response 58 Adverse events 58 hemoglobin Hb 58 paclitaxel eluting stents 58 sustained virological response 58 balsalazide 58 arterial thromboembolic 58 RECIST 58 ARIXTRA 58 achieved CCyR 58 DOXIL 58 KAPIDEX 58 detectable HCV RNA 58 apolipoprotein B 58 echocardiographic 58 histologically confirmed 58 LEXIVA 58 histological subtype 58 hypomagnesemia 58 adjuvant therapies 58 nonhematologic adverse reactions 58 Timed Walk 58 PANSS scores 58 sirolimus eluting stents 58 sumatriptan naproxen sodium 58 systemic embolism 58 ABC/3TC 58 -#.# mg dL [001] 58 Adalimumab 57 rimonabant #mg 57 Targretin capsules 57 treatment emergent adverse 57 daunorubicin 57 CDAI score 57 hypophosphatemia 57 mg BID dose 57 analgesic efficacy 57 amoxicillin clavulanate 57 multivariate logistic regression 57 INVEGA ® 57 TURBT 57 Rating Scale UPDRS 57 salmeterol inhalation powder 57 drug eluting stent implantation 57 multivariate Cox 57 Fasting plasma glucose 57 fluoropyrimidine 57 plus MTX 57 ularitide 57 assessing T DM1 57 -#.# mg dL [002] 57 hematologic toxicity 57 hematological toxicities 57 plasma pharmacokinetics 57 alanine aminotransferase ALT 57 avosentan 57 AVANDIA 57 thrombocytopenic 57 #mg/m# [002] 57 events AEs 57 selective modulator 57 urine albumin 57 statistical significance p 57 fibrinolytic therapy 57 mapatumumab 57 point Likert scale 57 docetaxel Taxotere ® 57 mediated dilation 57 ginkgo extract 57 ALT flares 57 Hb A1C 57 renal toxicity 57 iniparib 57 μg dose 57 cytopenias 57 #μg [002] 57 INFERGEN 57 duplex ultrasonography 57 ACTEMRA 57 LDB CPR 57 TAXUS Stent 57 glomerular filtration rate 57 bupropion SR 57 evaluating tivozanib 57 vidofludimus 57 SCr 57 azacytidine 57 atherogenic dyslipidemia 57 ARB telmisartan 57 esophageal carcinoma 57 ziprasidone 57 steroid dexamethasone 57 acutely decompensated congestive heart 57 fluvastatin 57 rizatriptan 57 antiretroviral naïve 57 abciximab 57 alanine aminotransferase 57 hypercholesterolaemia 57 Kaplan Meier method 57 BPS IC 57 clomipramine 57 TMC# r 57 baseline LDH 57 linaclotide treated 57 DAS# scores 57 SPIRIT FIRST 57 Main Outcome Measure 57 fenofibric acid 57 idarubicin 57 ACTIVE W 57 recurrent venous thromboembolism 57 leucopenia 57 splenectomized 57 refractory chronic lymphocytic 57 metastatic castration resistant 57 OPT CHF 57 BYSTOLIC 57 neoadjuvant chemotherapy 57 alpha 2a 57 caspofungin 57 left ventricular LV 57 p = 57 RE LY ® 57 macrovascular events 57 EDEMA3 57 glomerular filtration 57 locoregional 57 EFAPROXYN 57 nonvertebral fracture 57 radiochemotherapy 57 bypass graft CABG surgery 57 apnea hypopnea 57 ischemia driven 57 nadroparin 57 placebo controlled Phase III 57 platinum refractory 57 ischemic complications 57 ACCORD Lipid 57 micafungin 57 aldosterone antagonists 57 bronchial hyperresponsiveness 57 rotigotine 57 peginterferon 57 beclomethasone dipropionate 57 Lantus ® 57 left ventricular diastolic 57 blinded randomized placebo controlled 57 myocardial infarction ventricular fibrillation 57 antiarrhythmic medications 57 psychopathological symptoms 57 fraction LVEF 57 spirometric 57 antidiabetic medications 57 CorVue ™ 57 APPRAISE 57 mg/m2/day 57 alvimopan 57 tumor lysis syndrome 57 plus ribavirin 57 Fulvestrant 57 intravenous bisphosphonates 57 pamidronate 57 electrophysiologic 57 Xanafide 57 ventricular tachyarrhythmia 57 #mg dose [003] 57 FOSRENOL ® 57 Fibromyalgia Impact Questionnaire 57 Tanespimycin 57 HOMA IR 57 mild renal insufficiency 57 patients undergoing CABG 57 Seattle Angina Questionnaire 57 favorable pharmacokinetic profile 57 thromboembolic complications 57 PROMACTA 57 pharmacokinetics 57 cilostazol 57 Pemetrexed 57 CI -#.# 57 UACR 57 CINQUIL 57 triiodothyronine 57 Dacogen injection 57 diameter stenosis 57 liver transplant recipients 57 darunavir ritonavir 57 Hamilton Anxiety Scale 57 olanzapine LAI 57 romiplostim 57 recurrent ischemia 57 virologic breakthrough 57 equi analgesic doses 57 receiving prophylactic anticoagulation 57 HORIZONS AMI trial 57 NEVO ™